Greer Launches Phase III Trial to Study Efficacy of Sublingual-Oral Immunotherapy in Patients with Allergic Rhinoconjunctivitis

LENOIR, N.C.--(BUSINESS WIRE)--Greer, a leading developer and provider of allergy immunotherapy products and services, announced today the launch of a Phase III randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy of sublingual-oral immunotherapy (SLIT) in adults with allergic rhinoconjunctivitis caused by short ragweed pollen. Greer is the first U.S. allergy company to initiate a Phase III trial for the oral administration of liquid standardized allergenic extracts.